| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 1.4, positive 2.6, negative -1.3) on 20251103. The forces of Price Level (2), Sentiment towards Fundamentals (1.7), Option Speculation (1.5), and Sector Price Trend (-0.6) will drive up the price. The forces of Broad Market Trend (-0.9), Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. May short with small fund allocation when appropriate.The swing to upside will be significant considering the high positive sentiment forces (2.6). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-03 | 2% | 1.7% | 144.41 | 54 | 0.12% | 0% | 0.3 | -0.5 | 1.7 | 2.7 |
| 2025-11-02 | 1% | 1.6% | 1.2 | -0.3 | 1.8 | 0 | ||||
| 2025-11-01 | 1% | 1.6% | 1.1 | -0.3 | 1.7 | 1.5 | ||||
| 2025-10-31 | 2% | 1.4% | 144.23 | 51 | -0.05% | 0.07% | 1.1 | -0.3 | 1.7 | 3.5 |
| 2025-10-30 | 3% | 1.3% | 144.3 | 52 | 0.17% | 0.14% | 1.1 | -0.4 | 2 | 4.9 |
| 2025-10-29 | 1% | 1% | 144.05 | 47 | -0.95% | 0.07% | 1.7 | -0.4 | 2.1 | -0.9 |
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| 2025-10-27 | 1% | 1% | 146.38 | 87 | 0.23% | 0.35% | 1.5 | 0.3 | 1.9 | 2.9 |
| 2025-10-26 | 1% | 1% | 1.3 | 0.4 | 2 | 1 | ||||
| 2025-10-25 | 0% | 0.9% | 1.3 | 0.4 | 2 | 0 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (2) $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS Are Intuitive Surgical insiders cashing out after its October earnings surge? See the signals insiders are sending at KMI, ISRG, and QuantumScape. (https://www.marketbeat.com/) Mon. Nov 3, 2025 | |
| 2 (-7) Major diabetes health care company files Chapter 11 bankruptcy The healthcare technology company, which provides services to high-risk diabetes patients, files for bankruptcy protection (https://www.thestreet.com/) Mon. Nov 3, 2025 | |
| 3 (8) The Ensign Group, Inc. Q3 Profit Increases, Beats Estimates The Ensign Group, Inc. (ENSG) released earnings for its third quarter that Increased from last year and beat the Street estimates. The company's earnings came in at $83. (https://www.rttnews.com/) Mon. Nov 3, 2025 | |
| 4 (1) Inspire Medical Systems, Inc. Q3 Profit Decreases, But Beats Estimates Inspire Medical Systems, Inc. (INSP) announced earnings for third quarter that Decreased from last year but beat the Street estimates. The company's earnings came in at $9. (https://www.rttnews.com/) Mon. Nov 3, 2025 | |
| 5 (0) Pediatrix Medical Group Inc. Complete Pediatrix Medical Group Inc. stock information by Barron's. View real-time MD stock price and news, along with industry-best analysis. (https://www.barrons.com/) Mon. Nov 3, 2025 | |
| 6 (7) Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill Hims & Hers Health Inc. rose in late trading after the telehealth company said it was in talks with Novo Nordisk A/S to make its new obesity pill available on the company’s site. (https://www.bloomberg.com/) Mon. Nov 3, 2025 | |
| 7 (7) Hims & Hers Stock Pops After Q3 Earnings: Here's Why Here's a look at the Q3 earnings report from Hims & Hers Health. (https://www.benzinga.com/) Mon. Nov 3, 2025 | |
| 8 (7) Cigna Group stock outperforms competitors on strong trading day Shares of Cigna Group CI rallied 5.81% to $258.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 6,851.97 and the Dow Jones Industrial Average DJIA falling 0.48% to 47,336.68. The stock's rise snapped a four-day losing streak. (https://www.marketwatch.com/) Mon. Nov 3, 2025 | |
| 9 (8) IDEXX Laboratories Inc. stock outperforms competitors on strong trading day Shares of IDEXX Laboratories Inc. IDXX jumped 14.84% to $722.94 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 6,851.97 and the Dow Jones Industrial Average DJIA falling 0.48% to 47,336.68. This was the stock's third consecutive day of gains. (https://www.marketwatch.com/) Mon. Nov 3, 2025 | |
| 10 (7) Is UnitedHealth an Undervalued Stock to Buy Now? UnitedHealth is looking forward to the next calendar year when it can raise prices on an important customer segment. (https://www.fool.com/) Mon. Nov 3, 2025 | |
| 11 (-6) Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech... (https://finance.yahoo.com/) Mon. Nov 3, 2025 | |
| 12 (-5) Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal President Donald Trump has claimed Kenvue’s pain reliever is a potential cause of autism, despite clear evidence. (https://www.forbes.com/) Mon. Nov 3, 2025 | |
| 13 (-5) Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit in four days as Pfizer tries to retain its grip on a deal that Novo upended last week. (https://www.bloomberg.com/) Mon. Nov 3, 2025 | |
| 14 (8) Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook Idexx stock gains after Q3 earnings and revenue beat expectations, driven by strong CAG growth and raised 2025 earnings and sales guidance. (https://www.benzinga.com/) Mon. Nov 3, 2025 | |
| 15 (8) Kenvue jumps 22% on $48.7 billion Kimberly-Clark merger deal Kenvue jumps 22% on $48.7 billion Kimberly-Clark merger deal (https://www.investing.com/) Mon. Nov 3, 2025 | |
| 16 (-7) As Congress Holds Up Obamacare Tax Credits, Insurers Hike Prices And Lose Customers The nation’s health insurers have hiked Obamacare prices to boost profits while bracing for losses of customers who cannot afford to buy more expensive coverage. (https://www.forbes.com/) Sun. Nov 2, 2025 | |
| 17 (7) Cigna’s Rebate-Free Pharmacy Model Holds Promise For Some Patients Cigna says it will “transition toward a new model where discounts negotiated with drug companies are available upfront to Americans buying their medications.” (https://www.forbes.com/) Sun. Nov 2, 2025 | |
| 18 (0) 1 Stock to Buy, 1 Stock to Sell This Week: Palantir, Pfizer Market Analysis by covering: S&P 500, SPDR® S&P 500® ETF Trust, Invesco QQQ Trust, Pfizer Inc. Read 's Market Analysis on Investing.com (https://www.investing.com/) Sun. Nov 2, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA